through the Integration of Biosensing and AI
Ultra-Precision Sensing Technology
Model BA200
Designed for non-invasive point-of-care assessment of airway inflammation, this device combines high-sensitivity biosensor technology (0.1 ppb) with full ATS/ERS compliance. It delivers multi-parameter results—FeNO, CaNO, FnNO—in under one minute, while a patented dual-channel design ensures complete protection against cross-contamination.
More
Driven by a passion for innovation and a commitment to excellence, desire to maintain high levels of innovation, knowledge, technical expertise, service.
Committed to providing solutions for respiratory diseases, cardiovascular diseases and metabolic diseases
Become a global provider in comprehensive chronic disease solution for both professional segment and homecare.
Asthma symptoms are nonspecific, so diagnosis requires objective confirmation of variable airflow limitation. Spirometry with bronchodilator responsiveness—FEV₁ improvement of ≥12% and ≥200 mL—is the cornerstone. FeNO and blood eosin...
Fractional nasal nitric oxide (FnNO) testing measures nitric oxide from the nose and sinuses during nasal breathing. Unlike FeNO, it reflects upper-airway biology. FnNO is non-invasive and changes with disease: often elevated in allergic ...
FeNO testing is highly flow-dependent: exhaled flow rate determines which airway compartment is sampled. The standard 50 mL/s maneuver—a slow, steady exhalation against mild resistance for 6–10 seconds—primarily reflects large-airway b...
Please complete the form to contact our team